Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6353-6361

  Koido, Shigeo ^a   Kan, Shin ^a   Yoshida, Kosaku ^b   Yoshizaki, Shinji ^b   Takakura, Kazuki ^a   Namiki, Yoshihisa ^a   Tsukinaga, Shintaro ^a   Odahara, Shunichi ^a   Kajihara, Mikio ^a   Okamoto, Masato ^c   Ito, Masaki ^a   Yusa, Sei Ichi ^b   Gong, Jianlin ^d   Sugiyama, Haruo ^e   Ohkusa, Toshifumi ^a   Homma, Sadamu ^a   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tella Inc   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Chemoimmunotherapy; Gemcitabine; IFN ; Immunomodulation; PDL1; WT1

Indexed keywords

CALRETICULIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; HLA ANTIGEN; HLA DR ANTIGEN; MUCIN 1; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; DEOXYCYTIDINE; MESSENGER RNA; TUMOR ANTIGEN; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ADULT; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DEPRESSION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MIDDLE AGED; NEPHROBLASTOMA; PERITONEUM METASTASIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT REFUSAL; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTRAHEPATIC BILE DUCT; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE;

ANTIGENS, CD274; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHATIC METASTASIS; MIDDLE AGED; MUCIN-1; PERITONEAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 84916206244     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Furuse J and Okusaka T: Targeted therapy for biliary tract cancer. Cancers 3: 2243-2254, 2011.
2. Ramirez-Merino N, Aix SP and Cortes-Funes H: Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol 5: 171-176, 2013.
3. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L and Kroemer G: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007.
4. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S and Gameiro SR: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic Tlymphocytes and is distinct from immunogenic cell death. Int J Cancer 133: 624-636, 2013.
5. Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H and Homma S: Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother 60: 1289-1297, 2011.
6. Koido S, Homma S, Takahara A, Namiki Y, Komita H, Uchiyama K, Ito M, Gong J, Ohkusa T and Tajiri H: Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. Immunotherapy 4: 5-7, 2012.
7. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L and Kroemer G: Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14: 1848-1850, 2007.
8. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G and Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059, 2007.
9. Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T and Tajiri H: Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res 20: 4228-4239, 2014.
10. National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm, 2011.
11. Sugiyama H: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 4: 503-512, 2005.
12. Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y and Heike Y: Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 34: 92-99, 2011.
13. Kimura Y, Imai K, Shimamura K, Tsukada J, Tomoda T, Sunamura M, Shimodaira S, Yokokawa K, Koido S, Homma S and Okamoto M: Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 41: 195-205, 2012.
14. Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H and Sugiyama H: Wilms tumor gene 1 (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37: 105-114, 2014.
15. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F and Garrido F: The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53: 904-910, 2004.
16. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L and Kroemer G: Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from 'silent' to immunogenic. Cancer Res 67: 7941-7944, 2007.
17. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L and Kroemer G: Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334: 1573-1577, 2011.
18. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and Chen L: Colocalization of inflammatory response with B7H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127-137, 2012.
19. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A and Wigginton JM: Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
20. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M and Nakajima Y: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157, 2007.
21. + T-cells. Cancer Res 64: 1140-1145, 2004.
22. Butte MJ, Keir ME, Phamduy TB, Sharpe AH and Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 co-stimulatory molecule to inhibit T cell responses. Immunity 27: 111-122, 2007.
23. Zitvogel L and Kroemer G: Targeting PD1/PDL1 interactions for cancer immunotherapy. Oncoimmunology 1: 1223-1225, 2012.